Boston Scientific Corporation (BSX): Billionaire Tom Steyer Is Loading Up on This Stock

Why It Matters

The upgraded stake signals confidence in BSX’s growth pipeline, while its new device approvals could expand market share in high‑margin cardiac therapies, directly influencing investor sentiment and sector dynamics.

Key Takeaways

• Farallon Capital increased BSX stake to 7.4 M shares, +56% QoQ
• FARAPULSE PFA outperforms drugs for persistent atrial fibrillation
• WATCHMAN cleared as first‑line alternative to blood thinners
• Q1 2026 revenue $5.20 B beat forecasts; guidance trimmed
• Device pipeline drives interest from elite investors

Pulse Analysis

Boston Scientific’s recent surge in institutional ownership reflects a broader trend of elite investors gravitating toward medical‑device firms with differentiated product portfolios. Farallon Capital’s 56% quarter‑over‑quarter increase to 7.4 million shares signals strong conviction in BSX’s ability to capitalize on a growing cardiology market, especially as billionaire investors like Tom Steyer seek stable, cash‑generating assets amid market volatility.

The spotlight at Heart Rhythm 2026 on FARAPULSE PFA and the WATCHMAN device underscores BSX’s innovation edge. Clinical data showing FARAPULSE’s superiority over traditional antiarrhythmic drugs positions it to capture a sizable segment of patients with persistent atrial fibrillation, while the CHAMPION‑AF trial validates WATCHMAN as a safe, effective first‑line alternative to anticoagulants. These approvals not only broaden the addressable patient pool but also enhance pricing power and recurring revenue streams through device implantation and follow‑up services.

Financially, BSX delivered $5.20 billion in Q1 revenue, modestly beating consensus, yet the company lowered its full‑year guidance, reflecting cautious expectations amid supply‑chain pressures and competitive pricing. Analysts will watch whether the new device rollouts can offset the guidance cut and drive earnings momentum. For investors, the blend of robust clinical pipelines and renewed institutional backing makes Boston Scientific a compelling play in the med‑tech space, even as some analysts compare its upside potential to high‑growth AI stocks.